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Introduction
Coagulation factor XIII is a plasma transglutaminase that plays a critical role in maintaining hemostasis by simultaneously cross-linking fibrin with itself and various antifibrinolytic proteins, thereby enhancing both the mechanical strength of fibrin and its resistance to fibrinolysis [1] [2] [3] . The zymogen is a heterotetramer consisting of two A-subunits (FXIII-A) and two B-subunits (FXIII-B). Activation occurs upon dissociation of the B-subunits and thrombin-catalyzed cleavage of a 37-residue A-subunit activation peptide resulting in a conformational change of dimeric FXIII-A 2 to its catalytically active state.
Congenital FXIII deficiency is a rare, autosomal recessive coagulation disorder. The majority of reported cases (> 95%) result from A-subunit deficiency, caused by mutations of F13A1 [4] . Affected patients experience a significant hemorrhagic disorder that often presents in the neonatal period with umbilical stump hemorrhage (80% of patients) [2] . FXIII deficiency is also associated with high rates of intracranial hemorrhage (30%), impaired wound healing (14-29%), bruising (60%), hematomas (55%), mucosal bleeding (30%), menorrhagia (9%), and recurrent pregnancy loss [2, 5] . Thus, prophylactic FXIII supplementation, beginning early in life, has become the standard of care to prevent serious bleeding complications [6] [7] [8] [9] [10] [11] .
Until recently, the only options for FXIII supplementation were blood products and plasma-derived FXIII concentrate [12] . Recombinant FXIII-A (rFXIII), manufactured by Novo Nordisk A/S (Copenhagen, Denmark) through transgene expression in Saccharomyces cerevisiae, has recently been approved by international regulatory agencies for antihemorrhagic prophylaxis in patients with congenital FXIII-A deficiency [5, [13] [14] [15] . This approval was based on the results of a phase 3a study in which rFXIII prophylaxis was demonstrated to be safe and effective in patients aged ≥ 6 years [13] . The pharmacokinetics of rFXIII were subsequently described for adults, older children (≥ 6 years), and younger children (< 6 years) [5, 14, 15] . The objective of the phase 3b clinical trial presented here was to assess the safety and efficacy of long-term, monthly rFXIII prophylaxis in younger children (< 6 years).
Materials and methods

Design
All six patients who completed an rFXIII pharmacokinetic study were recruited into the present study [14] . Prior to entering these studies, they had all been receiving prophylaxis with a plasma-derived FXIII concentrate. At a combined screening, assessment and dosing visit, each patient received 35 IU kg À1 rFXIII intravenously. This dose was repeated every 28 days (AE 2 days) for a minimum of 52 weeks, extended until the product became commercially available, which varied by the timing of regulatory approval in each country. Laboratory and medical assessments were conducted at each dose visit for the first 48 weeks, and thereafter at least every 12 weeks. Information regarding adverse events and bleeding episodes was collected at each visit.
The study was performed in accordance with the Declaration of Helsinki and the International Conference on Harmonization, and Good Clinical Practice. Each participant provided informed consent. The study was registered at ClinicalTrials.gov (Number: NCT01253811).
Primary and secondary endpoints
The primary safety endpoint was defined as treatmentrelated serious and non-serious adverse events occurring between the first rFXIII administration and the end of the patient's participation in the trial. Secondary safety endpoints included inhibitory and non-inhibitory antibody development, laboratory parameters (including hematology, biochemistry, and coagulation parameters), physical examination, and vital sign abnormalities. Efficacy was a secondary endpoint assessed by the composite of the rate of treatment-requiring bleeds and number of subjects withdrawn owing to lack of efficacy (as judged by the investigator). Treatment-requiring bleeds were defined as any bleeding episodes requiring treatment with an FXIII-containing product other than rFXIII, including spontaneous, traumatic and intracranial hemorrhage (treatment with rFXIII for bleeding was not permitted during the study).
Assays
FXIII activity was assessed with the Berichrom FXIII activity assay (Siemens Healthcare Diagnostics, Munich, Germany), modified as previously published [5, [13] [14] [15] . The development of anti-rFXIII antibodies was assessed by ELISA, as previously described [13, 16, 17] . FXIII activity and anti-rFXIII antibody ELISA was assessed on pre-dose samples at each visit. Peak FXIII activity was measured on post-dose samples collected 1 h after the dose during the first 48 weeks of the study. FXIII-A 2 B 2 and free FXIII-B levels were quantified with ELISA assays as previously described [13, 14] .
Statistics
Serious and non-serious adverse events were summarized by event frequency and number of patients with any event. Adverse events were also cross-classified by event severity and causal relationship with rFXIII. The total numbers of bleeding events requiring and not requiring treatment with FXIII supplementation are presented. The total number of treatment-requiring bleeds was adjusted for time on study and presented as an annualized bleeding rate (ABR). Peak and trough FXIII activities are presented as geometric means (GMs) with coefficient of variation. Descriptive statistics are presented for all other variables.
Results and discussion
Six children with congenital FXIII-A deficiency as previously confirmed by genotype analysis and reported in the pharmacokinetic study were enrolled in this trial from five sites (Israel, 1; UK, 3; and USA, 2) [14] . All six children were receiving other prophylactic FXIII therapies prior to rFXIII study exposure. The three girls and three boys had an average age of 3.0 years (range: 1-4 years) at the time of enrollment (Table 1A) . One patient withdrew from the study after 84 weeks, because of family obligations precluding continued participation, but had completed the 52-week minimum study duration. The remaining five patients completed the study, and all six patients were included in the safety and efficacy analyses.
The six patients were exposed to a mean of 35.7 (standard deviation [SD] 8.6) doses per patient over a mean of 33.1 months (SD 8.1 months), collectively resulting in a total of 214 monthly doses of rFXIII given over a period of 16.6 patient-years for the cohort. Thus, although the sample size of this study is small, owing to the rarity of this bleeding disorder, no bleeding was observed over a prolonged duration of exposure.
Adverse events, evaluated and reported by the investigators, that occurred during the trial are summarized in Table 1B . Importantly, no anti-rFXIII antibodies (inhibitory or non-inhibitory) were detected in any patient during the trial. In contrast, spontaneously resolving noninhibitory anti-rFXIII antibodies were previously reported in children aged ≥ 6 years [13] . Two serious adverse events, unrelated to rFXIII, were reported; both occurred in the same patient, who was evaluated for head injury resulting from falls during play activities. Neither event resulted in intracranial hemorrhage. There were no adverse events attributable to thromboembolic events or deaths. Of the 100 adverse events occurring during the trial, 93% were mild and 7% were reported as moderate. The most frequently reported adverse events were upper respiratory infections (seven events in three patients), falls (seven events in three patients), and rhinorrhea (seven events in two patients).
Two adverse events, occurring in two patients, were rated by the on-site investigator as probably or possibly related to rFXIII. In the first case, viral gastroenteritis was reported 19 days after the rFXIII dose. The dose schedule was not changed, and the patient recovered fully. The second occurred in a 1-year-old male who was lymphocytopenic (1100 lymphocytes lL À1 ; institutional age-adjusted reference range, 2700-10 100) at his baseline visit. He was reported by the investigator to have occasional mild lymphocytopenia (2200-5500 lymphocytes lL À1 ) prior to enrollment. He continued to have mild, fluctuating lymphocytopenia (1100-2300 lymphocytes lL À1 ; institutional age-adjusted reference range, 2000-7800) throughout the course of the study. Subsequently, the study site reported that lymphocyte subset markers, mitogen stimulation, immunoglobulins and immunoglobulin-c subclasses were normal. In addition, the patient was reportedly able to mount appropriate specific antibody responses to immunizations. Several intercurrent viral infections that were not rated as related to rFXIII by the investigator were reported for this patient, and may have contributed to the fluctuating course of lymphocytopenia. The small sample size limits further analysis of a relationship between rFXIII and these adverse events; however, neither of these problems was identified in our previous trials [5, 13, 14, 18] . Otherwise, no clinically significant abnormalities in hematology, biochemistry or coagulation parameters were reported. These safety findings are consistent with the safety results from previous rFXIII trials in older age groups 0.000 E, number of adverse events; MESI, medical event of special interest; N, number of subjects with an adverse event; SD, standard deviation; w2, withdrawn per investigators' discretion (the family went on holiday for a longer period of time than permitted in the study protocol). MESIs for this study were: medication errors, transmission of infectious diseases via the trial product (rFXIII), formation of antibodies against rFXIII, thromboembolic events, anaphylactic reactions, and allergic reactions.
and in the previous pharmacokinetic study, where few adverse events were found to be related to rFXIII by the investigators, a low number of serious adverse events were reported, and no inhibitory rFXIII antibodies were identified [5, 13, 14] .
Six medical events of special interest (MESIs) (a priori defined as events of scientific or medical interest, including: medication errors, transmission of infectious diseases via trial product, development of antibodies against rFXIII, thromboembolic events, and anaphylactic and allergic reactions) were reported in four patients (Table 1B) . Three of these were classified as incorrect administration of rFXIII (one incorrect dose and two infusion site extravasations); the remaining 211 of 214 doses were administered correctly. The remaining three MESIs were skin rashes reported in a single patient on three separate occasions, all of which were reportedly atopic dermatitis. All six MESIs were thought to be unrelated to rFXIII by the investigators, and all of the patients recovered uneventfully. All six children showed normal growth, as assessed by body weight charted on standardized growth charts (data not shown) [19] . There were no treatment-requiring bleeding episodes during the trial, and no patients withdrew from the trial because of lack of efficacy. Thus, with no bleeds occurring, the planned Poisson analysis was not feasible, and the ABR was assumed to be zero (Table 1C ). There were, however, 14 minor bleeding episodes (eight minor trauma, five epistaxis, and one bruising) reported in five patients. Ten (71%) of these occurred > 10 days after the most recent dose of rFXIII. None of these bleeding episodes required treatment. These efficacy results are consistent with those reported previously, when very low rates of treatment-requiring bleeds were observed in older children and adults (0-0.138 ABR) [5, 13] .
Individual trough FXIII activity levels, obtained 30 min before the dose, were all above 0.1 IU mL
À1
, with the exception of a single trough for one patient whose subsequent troughs were > 0.1 IU mL À1 . This resulted in an overall GM trough FXIII activity for all subjects and time points of 0.19 IU mL À1 (Fig. 1A) . The GM peak FXIII activity, obtained 1 h after the dose, was 0.78 IU mL
. There were no apparent changes in the GM pre-dose or post-dose FXIII activities during the course of the trial. Although the FXIII assay used in this study may overestimate activity, especially at the lower limit of quantification (0.1 IU mL À1 ) [5] , the activities reported here were above this value and are consistent with the zero ABR. The 35 IU mL À1 every 28 AE 2 day regimen was chosen to maintain trough FXIII activity > 0.1 IU mL À1 , based on previous analyses [5, [13] [14] [15] 18] .
Interestingly, in this multiple-dose study, the GM trough FXIII activity was identical to that previously reported for the same cohort during a single-dose comprehensive pharmacokinetic study, in which FXIII activity was assessed at six time points [14] . As previously reported, FXIII-A 2 B 2 levels were reflective of FXIII activity, whereas free FXIII-B levels dropped sharply following rFXIII administration, with recovery prior to the next dose (Fig. 1B,C) [13, 14] . This study was limited in size by the rarity of FXIII deficiency; thus, the power to detect rFXIII antibodies, as previously reported [13] , is impaired. Similarly, infrequent breakthrough bleeding was also reported previously, and may have been detected with a larger sample [13] . Although it would be reasonable to hypothesize that earlier initiation of treatment may protect this younger group from breakthrough bleeding, this study was not designed to directly compare the efficacy or safety of rFXIII with other replacement therapies.
In the current study of prophylactic rFXIII treatment in young children with FXIII-A deficiency, there were no serious adverse events considered to be related to rFXIII by the investigator, there were two adverse events possibly related to rFXIII, and there were 98 adverse events unrelated to rFXIII. Six minor bleeding episodes, which did not require additional FXIII replacement therapy, were reported. No patients developed anti-rFXIII antibodies. An ABR (for treatment-requiring bleeding episodes) of zero was demonstrated over a period of 16.6 patient-years. This study thus adds to our overall knowledge regarding the safety and efficacy profile of rFXIII for pediatric patients with congenital FXIII-A deficiency. 
